docetaxel anhydrous has been researched along with tak 385 in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (tak 385) | Trials (tak 385) | Recent Studies (post-2010) (tak 385) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 75 | 21 | 73 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | tak 385 (IC50) |
|---|---|---|---|
| Gonadotropin-releasing hormone receptor | Homo sapiens (human) | 0.0039 | |
| Gonadotropin-releasing hormone receptor | Rattus norvegicus (Norway rat) | 0.0003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bossi, A; Brown, B; Buckley, D; Cookson, MS; George, DJ; Lu, S; Saad, F; Saltzstein, DR; Selby, B; Shore, ND; Tombal, B; Tutrone, R | 1 |
1 trial(s) available for docetaxel anhydrous and tak 385
| Article | Year |
|---|---|
Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
Topics: Antineoplastic Agents, Hormonal; Docetaxel; Humans; Leuprolide; Male; Prostatic Neoplasms; Testosterone | 2023 |